U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283575) titled 'Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)' on Dec. 04.
Brief Summary: Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer receiving radiotherapy plus SOC with or without PD-1.
Study Start Date: Oct. 10
Study Type: OBSERVATIONAL
Condition:
Metastatic Colorectal Cancer ctDNA Surveillance
Intervention:
DIAGNOSTIC_TEST: Plasma ctDNA methylation profiling
Plasma ctDNA methylation profiling was performed using an optimized...